The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
PAAB exemption criteria
-
Hey @akar
Correspondences intended to promote the company’s services (e.g. sampling services), would be classified as Corporate messages. When such APS mention or allude to a healthcare product, they require review per section 7.4 of the Code. The subject line, the email body, any attachments, and any hyperlinks would be considered in our review. If you are unsure whether review is required for a specific instance, you could submit an opinion enquiring whether the APS is exempt. You can instruct us within that opinion submission to EITHER inform you of the required revisions to make it exempt, or to inform you of the required changes to make it acceptable. See the document Exemption Requests Policy and Procedure
